Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Inclusion Criteria:

1. Patients that meet the diagnostic criteria.
2. Patients with age ≥18 years.
3. Patients with residual lesion greater than 3 mm after the initial punch, measurable byvideo colposcopy and with major changes (Criteria from Rio 2011).
4. Patients that have a positive test to the oncogenic virus of the human papilloma (16, 18, 31, 33, 45, 52 and 58).
5. Patients who give their informed consent to participation in writing.
6. Patients who consent to perform the conization according to the study schedule.
7. Patients with normal laboratory parameters within the limits established in theinstitution (complete blood count, platelets and erythrosedimentation. In the case ofmale sex (vasectomy, use of condoms) while the treatment lasts.

Exclusion Criteria:

1. Patients who have received surgical, ablative, radiant, immunomodulatory orchemotherapy treatment 30 days before recruitment.
2. Patients pregnant or breastfeeding.
3. Patients with acute cervico-vaginal infections.
4. Patients with positive serology known to HIV and/or syphilis.
5. Patients with diseases that compromise the state of consciousness or their possibilityof collaboration.
6. Patients with a history of severe allergic history.
7. Patients who are participating in another research.